Dossier assessment

Voretigene neparvovec (vision loss due to inherited retinal dystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

Status
Status: Commission completed
Project no.
G19-10
Last updated

Report documents

  1. Dossier assessment

    Voretigene neparvovec (vision loss due to inherited retinal dystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    published on
    Document type
    PDF document, 179 kB, DE, not accessible

Additional information

Federal Joint Committee (G-BA)

2019-10-17 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
G19-10
Commission
Commission awarded on 09.04.2019 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Health Economics
Topic
Head and nerves
Note

In accordance with § 35a (para. 1, sentence 11) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the Voretigene neparvovec report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA Website.

Connected Projects

  1. Dossier assessment

    Voretigene neparvovec (inherited retinal dystrophy) – Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G22-09
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form